Skip to main content

Grafa News and Videos — Page 1560

Latest

Grafa

Greenwich LifeSciences files patent claims to double GP2 market opportunity

Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences, has filed new patent claims that could significantly expand the addressable market for its lead candidate, GLSI-100.

Read more: Greenwich LifeSciences files patent claims to double GP2 market opportunity
Grafa

Lifezone Metals achieves first PGM production from recycled catalytic converters

Lifezone Metals (NYSE:LZM) has announced the first successful production of platinum, palladium, and rhodium from U.S.-sourced spent automotive catalytic converters, marking a technical milestone for its proprietary Hydromet Technology.

Read more: Lifezone Metals achieves first PGM production from recycled catalytic converters
Grafa
Media

Ackman’s Pershing Square proposes $64B U.S. merger to relist Universal Music Group

Pershing Square, led by billionaire investor Bill Ackman, has proposed a transformative merger between its acquisition vehicle and Universal Music Group (UMG) to relocate the world’s largest music label’s primary listing to the New York Stock Exchange.

Read more: Ackman’s Pershing Square proposes $64B U.S. merger to relist Universal Music Group
Grafa

Organogenesis announces successful primary endpoint in PuraPly AM clinical trial

Organogenesis Holdings (NASDAQ:ORGO), a leader in regenerative medicine, has announced positive topline results from a prospective, multi-center randomized controlled trial (RCT) evaluating PuraPly AM for the treatment of diabetic foot ulcers (DFUs).

Read more: Organogenesis announces successful primary endpoint in PuraPly AM clinical trial

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift